112 related articles for article (PubMed ID: 27697998)
1. Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.
Nesbitt H; Byrne NM; Williams SN; Ming L; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Clin Cancer Res; 2017 Apr; 23(7):1797-1808. PubMed ID: 27697998
[No Abstract] [Full Text] [Related]
2. The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Nesbitt H; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Prostate; 2017 Nov; 77(15):1539-1547. PubMed ID: 28944496
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation results in time-dependent hypoxia in LNCaP prostate tumours: informed scheduling of the bioreductive drug AQ4N improves treatment response.
Ming L; Byrne NM; Camac SN; Mitchell CA; Ward C; Waugh DJ; McKeown SR; Worthington J
Int J Cancer; 2013 Mar; 132(6):1323-32. PubMed ID: 22915157
[TBL] [Abstract][Full Text] [Related]
4. Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.
Browne G; Nesbitt H; Ming L; Stein GS; Lian JB; McKeown SR; Worthington J
Br J Cancer; 2012 Nov; 107(10):1714-21. PubMed ID: 23073173
[TBL] [Abstract][Full Text] [Related]
5. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
6. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer.
Colquhoun AJ; Venier NA; Vandersluis AD; Besla R; Sugar LM; Kiss A; Fleshner NE; Pollak M; Klotz LH; Venkateswaran V
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):346-52. PubMed ID: 22614062
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation in LNCaP prostate tumour xenografts induces vascular changes and hypoxic stress, resulting in promotion of epithelial-to-mesenchymal transition.
Byrne NM; Nesbitt H; Ming L; McKeown SR; Worthington J; McKenna DJ
Br J Cancer; 2016 Mar; 114(6):659-68. PubMed ID: 26954717
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
9. Elevation of c-FLIP in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.
McCourt C; Maxwell P; Mazzucchelli R; Montironi R; Scarpelli M; Salto-Tellez M; O'Sullivan JM; Longley DB; Waugh DJ
Clin Cancer Res; 2012 Jul; 18(14):3822-33. PubMed ID: 22623731
[TBL] [Abstract][Full Text] [Related]
10. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
[TBL] [Abstract][Full Text] [Related]
11. Silibinin inhibits hypoxia-induced HIF-1α-mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: In vitro evidence and in vivo functional imaging and metabolomics.
Deep G; Kumar R; Nambiar DK; Jain AK; Ramteke AM; Serkova NJ; Agarwal C; Agarwal R
Mol Carcinog; 2017 Mar; 56(3):833-848. PubMed ID: 27533043
[TBL] [Abstract][Full Text] [Related]
12. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
[TBL] [Abstract][Full Text] [Related]
13. Micellar delivery of bicalutamide and embelin for treating prostate cancer.
Danquah M; Li F; Duke CB; Miller DD; Mahato RI
Pharm Res; 2009 Sep; 26(9):2081-92. PubMed ID: 19415464
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Marrocco DL; Tilley WD; Bianco-Miotto T; Evdokiou A; Scher HI; Rifkind RA; Marks PA; Richon VM; Butler LM
Mol Cancer Ther; 2007 Jan; 6(1):51-60. PubMed ID: 17218635
[TBL] [Abstract][Full Text] [Related]
15. Bicalutamide failure in prostate cancer treatment: involvement of Multi Drug Resistance proteins.
Colabufo NA; Pagliarulo V; Berardi F; Contino M; Inglese C; Niso M; Ancona P; Albo G; Pagliarulo A; Perrone R
Eur J Pharmacol; 2008 Dec; 601(1-3):38-42. PubMed ID: 18992739
[TBL] [Abstract][Full Text] [Related]
16. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
17. Apalutamide radio-sensitisation of prostate cancer.
Kakouratos C; Kalamida D; Lamprou I; Xanthopoulou E; Nanos C; Giatromanolaki A; Koukourakis MI
Br J Cancer; 2021 Nov; 125(10):1377-1387. PubMed ID: 34471256
[TBL] [Abstract][Full Text] [Related]
18. Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
Bordini J; Morisi F; Elia AR; Santambrogio P; Pagani A; Cucchiara V; Ghia P; Bellone M; Briganti A; Camaschella C; Campanella A
Clin Cancer Res; 2020 Dec; 26(23):6387-6398. PubMed ID: 32928793
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Ferrari AC; Alumkal JJ; Stein MN; Taplin ME; Babb J; Barnett ES; Gomez-Pinillos A; Liu X; Moore D; DiPaola R; Beer TM
Clin Cancer Res; 2019 Jan; 25(1):52-63. PubMed ID: 30224345
[TBL] [Abstract][Full Text] [Related]
20. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]